Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

292
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
292
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.9K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

9.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.4K
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions01:09

Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions

241
Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
241
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

6.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
6.1K
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

123
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
123

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidisciplinary telemedicine intervention for ICU recovery: the TelePORT feasibility randomized trial.

Critical care (London, England)·2026
Same author

The Impact of Centrally Acting Drug Burden at Discharge on Long-Term Outcomes Among ICU Survivors.

Critical care medicine·2026
Same author

Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

CellAwareGNN: Single-Cell Enhanced Knowledge Graph Foundation Model for Drug Indication Prediction.

bioRxiv : the preprint server for biology·2026
Same author

Institutional Trends in Penicillin Allergy: A New Era of Active Penicillin Allergy Delabeling.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Identifying and Resolving Drug-Related Problems in Geriatric Patients.

Hospital pharmacy·2026

Related Experiment Video

Updated: Sep 20, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.8K

Detecting Drug-Drug Interactions in COVID-19 Patients.

Eugene Jeong1, Anna K Person2, Joanna L Stollings3

  • 1Department of Biomedical Informatics, Vanderbilt University Medical Center and Vanderbilt University School of Medicine, Nashville, Tennessee, United States.

Studies in Health Technology and Informatics
|June 8, 2022
PubMed
Summary
This summary is machine-generated.

This study identified potential new drug-drug interactions (DDIs) in COVID-19 patients using FDA data. These findings aid in discovering unrecognized DDIs and improving patient safety through further clinical trials.

Keywords:
COVID-19Drug-Drug InteractionsFAERS

More Related Videos

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.0K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

Related Experiment Videos

Last Updated: Sep 20, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.8K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.0K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

Area of Science:

  • Pharmacovigilance
  • Computational Pharmacology
  • Infectious Diseases

Background:

  • Patients with COVID-19 and comorbidities often use multiple medications (polypharmacy).
  • Existing literature highlights known drug-drug interactions (DDIs) in COVID-19 patients, but many remain unrecognized.
  • Unrecognized DDIs can lead to adverse events, complicating patient management.

Purpose of the Study:

  • To discover novel drug-drug interactions (DDIs) in patients with COVID-19.
  • To leverage real-world data from the FDA Adverse Event Reporting System (FAERS) for DDI identification.
  • To validate potential DDIs against a gold standard database.

Main Methods:

  • Utilized the FAERS database (January 2020 - March 2021) for comprehensive data analysis.
  • Applied seven distinct algorithms to systematically discover potential DDIs.
  • Employed the Liverpool DDI database, validated by clinical trials, as a gold standard for confirmation.

Main Results:

  • Identified 2,516 potential drug-drug pairs associated with adverse events (AEs).
  • Confirmed 49 of these pairs using the Liverpool DDI database.
  • Highlighted 2,467 novel candidate DDIs for future clinical investigation.

Conclusions:

  • The FAERS database combined with informatics approaches offers a powerful method for identifying novel DDIs in COVID-19 patients.
  • This study provides a foundation for generating clinical trial hypotheses to investigate candidate DDIs.
  • The findings contribute to enhancing patient safety by uncovering previously unrecognized drug interactions.